James Francis Demarest
Adjunct Assistant Professor in the Department of Immunology

Jim is an accomplished scientific leader recognized internationally for: 
  • R&D Innovation:  lead and supported research programs, translational research teams, and impacted business strategy for R&D pipeline
  • Business Development:  subject matter expert for in-licensing review and advisory role informing business development strategy for R&D and diagnostics
  • Regulatory:  written and face-to-face interactions with regulatory authorities from pre-IND/IND through and after NDA submission
  • Strategic Partnerships:  initiated and lead pre-clinical, clinical, and post-approval phase international research
  • Commercialization:  scientific lead and advisor for commercial, marketing, and medical affairs efforts associated with product launches and life cycle management
  • Diagnostics:  directed diagnostic collaborations and provided technical advice for assays and algorithms used in routine clinical care across diverse geographic regions and markets

Jim joined ViiV Healthcare at its inception in November 2009.  As Global Head, Clinical Virology and Immunology, he provides global oversight and leads a group responsible for the virology, immunology and diagnostics associated with pre-clinical and clinical phase compounds as well as marketed products. He is also the Global Medical Lead for HIV Remission & Cure at ViiV Healthcare.  In this capacity, he leads and oversees implementation of the global strategy for research and development advancing scientific knowledge as well as treatment regimens/approaches leading to HIV remission and ultimately cure.

After earning his PhD from the George Washington University while conducting research at the NIH/NIAID in the laboratory of Dr’s Giuseppe Pantaleo and Anthony Fauci, he completed a post-doctoral research fellowship at Duke University in the laboratory of Dr’s Kent Weinhold and Dani Bolognesi. He is also an Adjunct Assistant Professor in the Duke University Department of Immunology. During his 18+ year tenure at ViiV Healthcare and legacy companies, he has led a variety of efforts in discovery phase as well as clinical development of novel antivirals, immune-based therapies and vaccines for the treatment of HIV-1 infection. He is a member of several external scientific research committees, including the IAS Industry Collaborative Group, the International Drug Resistance Workshop, the EU HIV Resistance Guidelines Panel, the Industry Pharmacogenetics Working Group and focus working groups of the Forum for Collaborative HIV Research, the High Point University Institutional Biosafety Committee (IBC), amongst others. As of August 2017, he has authored 34 publications with 4,757 citations, has been an invited speaker at multiple international scientific events, and has more than 75 conference presentations.

Current Appointments & Affiliations

Contact Information

  • 207 Research Drive, Jones Building, Durham, NC 27710
  • Duke Box 3010, Durham, NC 27710

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.